Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients
PHILADELPHIA—With new competition potentially on its way in the PCSK9 inhibitor class, Amgen's stalwart Repatha is looking for a leg up in treating high-risk heart attack patients.
A new analysis shows that patients within the one-year mark of a heart attack are at a much higher risk of a following cardiovascular event––and cholesterol-lowering Repatha is particularly effective in treating that group.
Patients treated with a Repatha-statin combo within one year after a heart attack showed a 25% risk reduction in follow-up CV events, including heart attack, death or stroke, over statins alone. In patients treated with the combo after the one-year mark, there was a reported 15% risk reduction, according to an analysis of data from Amgen's Fourier outcomes trial set to be presented Monday at the American Heart Association's Scientific Sessions.